New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

Core Viewpoint - Roche's Gazyva/Gazyvaro (obinutuzumab) shows significant efficacy in treating systemic lupus erythematosus (SLE), with results from the phase III ALLEGORY trial published in the New England Journal of Medicine indicating a potential new standard of care for SLE patients [1][3][9]. Group 1: Trial Results - In the ALLEGORY trial, 76.7% of patients treated with Gazyva/Gazyvaro plus standard therapy achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at 52 weeks, compared to 53.5% with placebo, showing an adjusted difference of 23.1% (p<0.001) [1][2]. - Gazyva/Gazyvaro demonstrated superiority over placebo in all key and additional secondary endpoints, including a median time to first flare of 52.3 weeks for placebo, with a hazard ratio of 0.58 (p=0.002) [2][8]. - The remission rate was more than doubled, with 35.1% of patients on Gazyva/Gazyvaro achieving remission compared to 13.8% on placebo, an adjusted difference of 21.2% (p<0.001) [2][8]. Group 2: Clinical Implications - The results indicate that Gazyva/Gazyvaro can provide significant and sustained disease control, reducing reliance on steroids, which is crucial for improving patient quality of life [3][9]. - The study's findings are expected to influence health authorities, including the US FDA and European Medicines Agency, to expedite the approval process for Gazyva/Gazyvaro as a treatment for SLE [3][9]. - If approved, Gazyva/Gazyvaro would be the first Type II anti-CD20 therapy targeting B cells in SLE, addressing a key driver of disease activity [3][9]. Group 3: Safety and Additional Findings - Safety profiles for Gazyva/Gazyvaro were consistent with previous data, with no new safety signals identified during the trial [3][9]. - All five key secondary endpoints were met, including significant improvements in the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response and glucocorticoid reduction [3][8]. Group 4: Background on SLE - Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease affecting over three million people globally, predominantly women aged 15 to 45 [12][13]. - The disease can lead to severe organ damage and complications such as lupus nephritis, which affects approximately half of SLE patients within five years of diagnosis [12][13]. Group 5: Roche's Commitment - Roche aims to be a leader in immunology, with Gazyva/Gazyvaro being part of a broader pipeline targeting immune-mediated diseases [9][10]. - The company is committed to developing innovative therapies that improve patient outcomes and address unmet medical needs in autoimmune diseases [14][15].